Dr Roditi drafted the recent RCR guidance on gadolinium-based contrast agent administration to adult patients. This webinar is aimed at all healthcare professionals involved in MRI for adult patients where GBCAs may be used. We will explore the background to the current safety concerns around the use of GBCAs and subsequent regulatory changes. The presentation will outline the background in terms of physiochemical differences between the classes of GBCAs and an account of the issues around the very rare condition Nephrogenic Systemic Fibrosis, from the elucidation of the link to GBCA administration in patients with advanced renal failure and the subsequent effective eradication of this condition. The more recent concerns regarding gadolinium retention will then be explored and the impact of the most recent regulatory changes discussed. There will be the opportunity for questions and a guide on where to discover more about the issues raised.Led by Dr Giles Roditi, immediate past-President of the BSCI, the BSCI Travelling Professor and President of the Society of Magnetic Resonance Angiography. Horizontal Tabs